{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:52:55Z","timestamp":1758477175531},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T00:00:00Z","timestamp":1485561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007747","name":"Red Espa\u00f1ola de Esclerosis M\u00faltiple","doi-asserted-by":"publisher","award":["RETICS\u2010REEM RD12\/0032\/0009"],"award-info":[{"award-number":["RETICS\u2010REEM RD12\/0032\/0009"]}],"id":[{"id":"10.13039\/501100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>One of the risk factor to develop progressive multifocal leukoencephalopathy (<jats:styled-content style=\"fixed-case\">PML<\/jats:styled-content>) among natalizumab\u2010treated patients is the presence and high levels of anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibodies. Our purpose was to test the association of different clinical and demographic variables with the presence and levels of anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibodies in a Spanish cohort of patients with multiple sclerosis (<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>) during natalizumab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>All patients with <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> from two hospitals with at least one measure of the anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibodies levels (2011\u20132014) were recruited, among them were two <jats:styled-content style=\"fixed-case\">PML<\/jats:styled-content> cases. Anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibody levels were assessed using two\u2010step <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1061 patients (16\u00b73% natalizumab\u2010treated) participated in this study. The seropositivity rate of anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibodies was 58\u00b72%. It increased with age (<jats:italic>P<\/jats:italic><jats:sub>corrected<\/jats:sub> = 0\u00b700005) and was lower among <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRB<\/jats:styled-content>1*15:01 carriers (<jats:italic>P<\/jats:italic><jats:sub>corrected<\/jats:sub> = 0\u00b7049). The two patients with <jats:styled-content style=\"fixed-case\">PML<\/jats:styled-content> were <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRB<\/jats:styled-content>1*15:01 carriers. We had at least three quarterly anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibody measurements (index value) from 137 patients, whose levels did not increase during natalizumab treatment. However, 5\u00b78% of these patients had an increase of the index value higher of one point in a maximum of 6 months, something that was more frequently observed (<jats:italic>P<\/jats:italic> = 0\u00b7054) among patients treated with immunosuppressant prior to natalizumab onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Old age and <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRB<\/jats:styled-content>1*15:01 were the factors that influence positively and negatively, respectively, our anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibody prevalence, although our both <jats:styled-content style=\"fixed-case\">PML<\/jats:styled-content> cases were <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRB<\/jats:styled-content>1*15:01carriers. Most of our patients showed a stable anti\u2010<jats:styled-content style=\"fixed-case\">JCV<\/jats:styled-content> antibody index values during natalizumab treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.12721","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T14:52:41Z","timestamp":1483109561000},"page":"158-166","source":"Crossref","is-referenced-by-count":12,"title":["Study of the anti\u2010<scp>JCV<\/scp> antibody levels in a Spanish multiple sclerosis cohort"],"prefix":"10.1111","volume":"47","author":[{"given":"Mar\u00eda I.","family":"Dominguez\u2010Mozo","sequence":"first","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Rus","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Santiago","sequence":"additional","affiliation":[{"name":"Immunology Department Hospital Cl\u00ednico San Carlos IdISSC Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Casanova","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Galan","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Angel","family":"Garcia\u2010Martinez","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Arias\u2010Leal","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Garc\u00eda\u2010Montojo","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"P\u00e9rez\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Quir\u00f3n Salud Madrid Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Alvarez\u2010Lafuente","sequence":"additional","affiliation":[{"name":"Neurology Department Hospital Cl\u00ednico San Carlos Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_2_8_3_1","first-page":"117","article-title":"Stratification and monitoring of natalizumab\u2010associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan C","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24345"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a351fb"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0365-x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004084"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.10.003"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.05.004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2008.01101.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304332"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2014.32"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182583022"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12304"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000195"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12988"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.03.050"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/861091"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513477925"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513505353"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6487-5"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.11.031"},{"key":"e_1_2_8_27_1","first-page":"807","article-title":"JC virus antibody index in natalizumab\u2010treated patients: correlations with John Cunningham virus DNA and C\u2010reactive protein level","volume":"10","author":"Lanzillo R","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515599681"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514567728"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feci.12721","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.12721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T21:09:35Z","timestamp":1696367375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/eci.12721"],"URL":"https:\/\/doi.org\/10.1111\/eci.12721","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,28]]}}}